Garralda, Elena http://orcid.org/0000-0002-4412-7842
Beaulieu, Marie-Eve
Moreno, Víctor http://orcid.org/0000-0001-6099-4236
Casacuberta-Serra, Sílvia
Martínez-Martín, Sandra http://orcid.org/0000-0003-4443-0697
Foradada, Laia
Alonso, Guzman
Massó-Vallés, Daniel http://orcid.org/0000-0003-4231-0456
López-Estévez, Sergio
Jauset, Toni
Corral de la Fuente, Elena
Doger, Bernard
Hernández, Tatiana http://orcid.org/0000-0003-3459-871X
Perez-Lopez, Raquel
Arqués, Oriol
Castillo Cano, Virginia
Morales, Josefa
Whitfield, Jonathan R. http://orcid.org/0000-0002-4925-7283
Niewel, Manuela
Soucek, Laura http://orcid.org/0000-0002-4750-7971
Calvo, Emiliano http://orcid.org/0000-0003-4921-829X
Article History
Received: 7 February 2023
Accepted: 4 January 2024
First Online: 6 February 2024
Competing interests
: E.G. is Consultant-Advisor for Roche/Genentech, F.Hoffmann/La Roche, Ellipses Pharma, Neomed Therapeutics1, Inc., Boehringer Ingelheim, Janssen Global Services, SeaGen, TFS, Alkermes, Thermo Fisher, Bristol-Myers Squibb, MabDiscovery, Anaveon, F-Star Therapeutics and Hengrui. L.S. is Consultant and CEO of Peptomyc. V.M. is Consultant of Roche, Bayer, BMS, Janssen and Basilea. E.C. is Consultant-Advisor for Nanobiotix, Janssen-Cilag, Roche-Genentech, TargImmune Therapeutics, Servier, Bristol-Myers Squibb, Amunix, Adcendo, Anaveon, AstraZeneca/Medimmune, Chugai Pharma, MonTa, MSD Oncology, Nouscom, OncoDNA, T-Knife, Elevation Oncology, PharmaMar, Ellipses Pharma, Syneos Health, Genmab and Diaccurate. Employment. M.-E.B., S.C.-S., S.M.-M., L.F., S.L.-E., V.C.C., J.M., M.N. and L.S. are employees of Peptomyc. E.C. is an employee of START. Personal financial interests: L.S. and M.-E.B. are cofounders and shareholders of Peptomyc and inventors of patent application no. WO2014180889 A8 that covers the use of the Omomyc miniprotein in medicine, held by VHIO and licenced to Peptomyc. S.C.-S., S.L.-E., L.F., J.R.W. and M.N. are also shareholders of Peptomyc. E.G. performs research for Novartis, Roche, Thermo Fisher, AstraZeneca, Taiho and BeiGene; she is in Speakers Bureau for Merck Sharp & Dohme, Roche, Thermo Fisher, Lilly and Novartis; she runs clinical trials as PI or Co-PI with Agios Pharmaceuticals, Amgen, Bayer, Beigene USA, Blueprint Medicines, BMS, Cellestia Biotech, Debiopharm, F.Hoffmann/La Roche, Ltd, Forma Therapeutics, Genentech, Inc., Genmab B.V., GSK, Glycotope Gmbh, Incyte Biosciences, Incyte Corporation, ICO, Kura Oncology, Inc, Lilly, S.A, Loxo Oncology, Inc, Macrogenics, Inc, Menarini Ricerche Spa, Merck, Sharp & Dohme de España, S.A, Nanobiotix, S.A, Novartis Farmacéutica, S.A, Pfizer, SLU, Pharma Mar, S.A.U, Pierre Fabre Medicament, Principia Biopharma, Inc., Psioxus Therapeutics, Ltd, Sanofi, Sierra Oncology, Inc, Sotio A.S and Symphogen A/S. V.M. is Principal Investigator and receives institutional funding from AbbVie, AceaBio, Adaptimmune, ADC Therapeutics, Aduro, Agenus, Amcure, Amgen, Astellas, AstraZeneca Bayer Beigene BioInvent International AB, BMS, Boehringer, Boheringer, Boston, Celgene, Daichii Sankyo, DEBIOPHARM, Eisai, e-Terapeutics, Exelisis, Forma Therapeutics, Genmab, GSK, Harpoon, Hutchison, Immutep, Incyte, Inovio, Iovance, Janssen, Kyowa Kirin, Lilly, Loxo, MedSir, Menarini, Merck, Merus, Millennium, MSD, Nanobiotix, Nektar, Novartis, Odonate Therapeutics, Pfizer, Pharma Mar, PharmaMar, Principia, PsiOxus, Puma, Regeneron, Rigontec, Roche, Sanofi, Sierra Oncology, Synthon, Taiho, Takeda, Tesaro, Transgene, Turning Point Therapeutics and Upshersmith. E.C. is Principal Investigator and receives institutional funding from START, Pharma Mar, EORTC, Sanofi, BeiGene, Novartis and Merus N.V.; he is a shareholder of START and Oncoart Associated and receives honoraria from HM Hospitales Group; he receives research funding from START; he is President and Founder of Foundation Investigational Therapeutics in Oncological Sciences; and he has a not-for-profit relationship with PharmaMar and the CRIS Cancer Foundation. The other authors declare no competing interests.